Cargando…

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Doan T. M., Williams, Trent, Horder, Sophie, Kritharides, Leonard, Vardy, Janette, Mandaliya, Hiren, Nordman, Ina I. C., Lynam, James, Bonaventura, Tony, Sverdlov, Aaron L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/
https://www.ncbi.nlm.nih.gov/pubmed/32824667
http://dx.doi.org/10.3390/jcm9082664
_version_ 1783577495153410048
author Ngo, Doan T. M.
Williams, Trent
Horder, Sophie
Kritharides, Leonard
Vardy, Janette
Mandaliya, Hiren
Nordman, Ina I. C.
Lynam, James
Bonaventura, Tony
Sverdlov, Aaron L.
author_facet Ngo, Doan T. M.
Williams, Trent
Horder, Sophie
Kritharides, Leonard
Vardy, Janette
Mandaliya, Hiren
Nordman, Ina I. C.
Lynam, James
Bonaventura, Tony
Sverdlov, Aaron L.
author_sort Ngo, Doan T. M.
collection PubMed
description Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. Methods and Results: We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.
format Online
Article
Text
id pubmed-7465018
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74650182020-09-04 Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab Ngo, Doan T. M. Williams, Trent Horder, Sophie Kritharides, Leonard Vardy, Janette Mandaliya, Hiren Nordman, Ina I. C. Lynam, James Bonaventura, Tony Sverdlov, Aaron L. J Clin Med Article Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associated with increased risks of adverse cardiovascular effects with bevacizumab have not been intensively studied. In this study, we determined factors associated with hospital admissions due to cardiovascular complications in patients who received bevacizumab for cancer treatment. Methods and Results: We retrospectively collected data for all patients treated with bevacizumab between the 1st January 2016 and the 31st December 2017 at the Hunter New England Local Health District. Patients’ characteristics and their medical history were obtained from hospital electronic medical records. Outcome data were sourced from the Institutional Cardiac and Stroke Outcomes Unit database. A total of n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications. MDPI 2020-08-18 /pmc/articles/PMC7465018/ /pubmed/32824667 http://dx.doi.org/10.3390/jcm9082664 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ngo, Doan T. M.
Williams, Trent
Horder, Sophie
Kritharides, Leonard
Vardy, Janette
Mandaliya, Hiren
Nordman, Ina I. C.
Lynam, James
Bonaventura, Tony
Sverdlov, Aaron L.
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
title Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
title_full Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
title_fullStr Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
title_full_unstemmed Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
title_short Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
title_sort factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/
https://www.ncbi.nlm.nih.gov/pubmed/32824667
http://dx.doi.org/10.3390/jcm9082664
work_keys_str_mv AT ngodoantm factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT williamstrent factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT hordersophie factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT kritharidesleonard factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT vardyjanette factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT mandaliyahiren factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT nordmaninaic factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT lynamjames factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT bonaventuratony factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab
AT sverdlovaaronl factorsassociatedwithadversecardiovasculareventsincancerpatientstreatedwithbevacizumab